Parsemus Foundation: Difference between revisions
Content deleted Content added
Sean orlov (talk | contribs) mNo edit summary Tags: Visual edit Mobile edit Mobile web edit |
No edit summary |
||
| Line 1: | Line 1: | ||
{{notability|date=April 2013}} |
{{notability|date=April 2013}} |
||
The '''Parsemus Foundation''' is an [[United States|American]] [[non-governmental organization]] whose stated objective is to advance low |
The '''Parsemus Foundation''' is an [[United States|American]] [[non-governmental organization]] whose stated objective is to advance low-cost [[evidence-based medicine]]s not pursued by the [[pharmaceutical industry]].<ref name='ORiordanin 2011-07-15'>{{cite news |last=O'Riordan |first=Michael |url=http://www.medscape.com/viewarticle/746456 |title=What Is the Parsemus Foundation? |work=Heartwire |publisher=[[Medscape]] |date=2011-07-15 |accessdate=2017-03-21 }}</ref> The foundation’s focus is on supporting small [[proof-of-concept]] studies and then pursuing press coverage of the results, so that the advances change treatment practice rather than disappearing into the scientific literature. Many of the studies supported involve low-cost approaches that are not under [[patent]]. |
||
==Background== |
==Background== |
||
Founded in 2005, Parsemus is an advocate of research into the plausibility of [[Reversible inhibition of sperm under guidance|RISUG]], a reversible [[male contraceptive]].<ref name='Haine 2010-07-05'> {{cite news | first = Rosie | last = Haine | title = Men need more contraceptive choice | date = 2010-07-05 | url = https://www.bbc.co.uk/news/10514490 | work = BBC News | accessdate = 2012-10-13}}</ref><ref name="Sainani 2012">{{cite journal |title=This Time It's a Guy Thing |journal=Stanford Magazine |date= September–October 2012 |last=Sainani |first=Kristin |url=https://alumni.stanford.edu/get/page/magazine/article/?article_id=55985 |accessdate=2017-03-21 }}</ref> The foundation began procuring RISUG's United States [[intellectual property]] rights in November 2010, completed the acquisition process in February 2012, and is for the past 96 months conducting [[toxicology testing|toxicology tests]] as an initial step towards [[Food and Drug Administration]] approval. Vasgel production has continually been delayed with targets missed from 2015, 2017 and 2018 based on Parsemus foundations own targets. |
Founded in 2005, Parsemus is an advocate of research into the plausibility of [[Reversible inhibition of sperm under guidance|RISUG]], a reversible [[male contraceptive]].<ref name='Haine 2010-07-05'> {{cite news | first = Rosie | last = Haine | title = Men need more contraceptive choice | date = 2010-07-05 | url = https://www.bbc.co.uk/news/10514490 | work = BBC News | accessdate = 2012-10-13}}</ref><ref name="Sainani 2012">{{cite journal |title=This Time It's a Guy Thing |journal=Stanford Magazine |date= September–October 2012 |last=Sainani |first=Kristin |url=https://alumni.stanford.edu/get/page/magazine/article/?article_id=55985 |accessdate=2017-03-21 }}</ref> The foundation began procuring RISUG's United States [[intellectual property]] rights in November 2010, completed the acquisition process in February 2012, and is for the past 96 months conducting [[toxicology testing|toxicology tests]] as an initial step towards [[Food and Drug Administration]] approval. Vasgel production has continually been delayed with targets missed from 2015, 2017 and 2018 based on Parsemus foundations own targets. |
||
<ref name='Beck 2011-06-14'> {{cite news | first = Melinda | last = Beck | title = 'Honey, It's Your Turn...' | date = 2011-06-14 | url = https://www.wsj.com/articles/SB10001424052702303848104576383730320049892 | work = The Wall Street Journal | accessdate = 2012-10-13}}</ref><ref> {{cite web | url = http://parsemusfoundation.org/Parsemus/New_male_contraceptives.html | title = Parsemus Foundation | accessdate = 2012-10-13 | deadurl = yes | archiveurl = https://web.archive.org/web/20121014135626/http://www.parsemusfoundation.org/Parsemus/New_male_contraceptives.html | archivedate = 2012-10-14 | df = }}</ref><ref name="Priceonomics">{{cite news |url=https://priceonomics.com/the-economics-of-male-birth-control/ |title=The Economics of Male Birth Control |work=Priceonomics |date=2015-10-19 |accessdate=2017-03-21 }}</ref> Animal trials have thus far proved effective with no negative side effects; human trials are being planned for 2015-2016 with missed market release in 2017<ref>http://www.parsemusfoundation.org/vasalgel-faqs/</ref> as of 2019. |
<ref name='Beck 2011-06-14'> {{cite news | first = Melinda | last = Beck | title = 'Honey, It's Your Turn...' | date = 2011-06-14 | url = https://www.wsj.com/articles/SB10001424052702303848104576383730320049892 | work = The Wall Street Journal | accessdate = 2012-10-13}}</ref><ref> {{cite web | url = http://parsemusfoundation.org/Parsemus/New_male_contraceptives.html | title = Parsemus Foundation | accessdate = 2012-10-13 | deadurl = yes | archiveurl = https://web.archive.org/web/20121014135626/http://www.parsemusfoundation.org/Parsemus/New_male_contraceptives.html | archivedate = 2012-10-14 | df = }}</ref><ref name="Priceonomics">{{cite news |url=https://priceonomics.com/the-economics-of-male-birth-control/ |title=The Economics of Male Birth Control |work=Priceonomics |date=2015-10-19 |accessdate=2017-03-21 }}</ref> Animal trials have thus far proved effective with no negative side effects; human trials are being planned for 2015-2016 with missed market release in 2017<ref>http://www.parsemusfoundation.org/vasalgel-faqs/</ref> as of 2019. |
||
The organization also offers resources on alternative methods of fertility control ([[neutering]]) for dogs and cats. Its focus has been on ovary-sparing spay for female dogs and cats, vasectomy for male dogs and cats, and non-surgical sterilization using calcium chloride-based formulations for male dogs and cats.<ref>{{Cite web|url=https://www.parsemus.org/|title=Parsemus Foundation|last=|first=|date=|website=|archive-url=|archive-date=|dead-url=|access-date=January 5, 2019}}</ref> |
|||
The foundation was also noted for its support of the ''[[Archives of Internal Medicine]]'''s ''less-is-more'' series.<ref name='ORiordanin 2011-07-15'/><ref name='Brownlee 2011-07-19'> {{cite news | first = Shannon | last = Brownlee | title = Less Is More | date = 2011-07-19 | url = http://health.newamerica.net/blogposts/2011/less_is_more-55062 | work = New America Foundation | accessdate = 2012-10-13 | deadurl = yes | archiveurl = https://web.archive.org/web/20120916035721/http://health.newamerica.net/blogposts/2011/less_is_more-55062 | archivedate = 2012-09-16 | df = }}</ref> |
The foundation was also noted for its support of the ''[[Archives of Internal Medicine]]'''s ''less-is-more'' series.<ref name='ORiordanin 2011-07-15'/><ref name='Brownlee 2011-07-19'> {{cite news | first = Shannon | last = Brownlee | title = Less Is More | date = 2011-07-19 | url = http://health.newamerica.net/blogposts/2011/less_is_more-55062 | work = New America Foundation | accessdate = 2012-10-13 | deadurl = yes | archiveurl = https://web.archive.org/web/20120916035721/http://health.newamerica.net/blogposts/2011/less_is_more-55062 | archivedate = 2012-09-16 | df = }}</ref> |
||
Revision as of 19:25, 4 January 2019
 | The topic of this article may not meet Wikipedia's general notability guideline. (April 2013) |
The Parsemus Foundation is an American non-governmental organization whose stated objective is to advance low-cost evidence-based medicines not pursued by the pharmaceutical industry.[1] The foundation’s focus is on supporting small proof-of-concept studies and then pursuing press coverage of the results, so that the advances change treatment practice rather than disappearing into the scientific literature. Many of the studies supported involve low-cost approaches that are not under patent.
Background
Founded in 2005, Parsemus is an advocate of research into the plausibility of RISUG, a reversible male contraceptive.[2][3] The foundation began procuring RISUG's United States intellectual property rights in November 2010, completed the acquisition process in February 2012, and is for the past 96 months conducting toxicology tests as an initial step towards Food and Drug Administration approval. Vasgel production has continually been delayed with targets missed from 2015, 2017 and 2018 based on Parsemus foundations own targets. [4][5][6] Animal trials have thus far proved effective with no negative side effects; human trials are being planned for 2015-2016 with missed market release in 2017[7] as of 2019.
The organization also offers resources on alternative methods of fertility control (neutering) for dogs and cats. Its focus has been on ovary-sparing spay for female dogs and cats, vasectomy for male dogs and cats, and non-surgical sterilization using calcium chloride-based formulations for male dogs and cats.[8]
The foundation was also noted for its support of the Archives of Internal Medicine's less-is-more series.[1][9]
References
- ^ a b O'Riordan, Michael (2011-07-15). "What Is the Parsemus Foundation?". Heartwire. Medscape. Retrieved 2017-03-21.
- ^ Haine, Rosie (2010-07-05). "Men need more contraceptive choice". BBC News. Retrieved 2012-10-13.
- ^ Sainani, Kristin (September–October 2012). "This Time It's a Guy Thing". Stanford Magazine. Retrieved 2017-03-21.
- ^ Beck, Melinda (2011-06-14). "'Honey, It's Your Turn...'". The Wall Street Journal. Retrieved 2012-10-13.
- ^ "Parsemus Foundation". Archived from the original on 2012-10-14. Retrieved 2012-10-13.
{{cite web}}: Unknown parameter|deadurl=ignored (|url-status=suggested) (help) - ^ "The Economics of Male Birth Control". Priceonomics. 2015-10-19. Retrieved 2017-03-21.
- ^ http://www.parsemusfoundation.org/vasalgel-faqs/
- ^ "Parsemus Foundation". Retrieved January 5, 2019.
{{cite web}}: Cite has empty unknown parameter:|dead-url=(help) - ^ Brownlee, Shannon (2011-07-19). "Less Is More". New America Foundation. Archived from the original on 2012-09-16. Retrieved 2012-10-13.
{{cite news}}: Unknown parameter|deadurl=ignored (|url-status=suggested) (help)
External links
 | This article related to a non-profit organization is a stub. You can help Wikipedia by expanding it. |